If you ask any long-time fan to name the best driver to never win a Cup Series championship, one name usually rises above the rest: Martin. But defining Mark Martin by what he didn’t win does a ...

Mark Martin reveals how he fought with NASCAR executives over the playoff format, stating that fans everywhere dislike the ...

Mark Martin says NASCAR committee talks included a full-season pointsas officials review possible playoff format changes for 2026.

NASCAR icon Mark Martin joins Paul Tracy on Racers Unchained for a wide-ranging, brutally honest conversation about racing, confidence, aging, and the evolution of the sport.

Mark Martin built a career that shatters the lazy idea that greatness is measured only in trophies. His record, his ...

Greg Biffle’s death has torn new wounds and reopened old ones. Mark Martin knows all too well the pain these tragic events can bring. It is a somber time in the NASCAR world as everyone tries to come ...

In case you thought that the 2026 ARCA Menards Series season was not worth watching, then ask Mark Martin what he thinks. Martin is ready to see what these young and developing drivers can do next ...

After general manager David Forst indicated he was “close on a couple of things” as he departed last week’s Winter Meetings in Orlando, Fla., the Athletics struck their first Major League deal of the ...

Pfizer sees $1.5 billion revenue drop from COVID products next year Pfizer's 2026 R&D expenses rise due to antibody development and clinical programs Pfizer's 2025 revenue forecast revised to about ...

With COVID sales falling and patent protections expiring, Pfizer is forecasting its 2026 revenue to be in the range of $59.5 billion to $62.5 billion. The midpoint of the projection ($61 billion) ...

Pfizer signaled Tuesday it expects a challenging 2026 as it invests in new products to offset declines in Covid-19 revenues while limiting shareholder payouts. Shares of the big drugmaker fell sharply ...

As 2025 closes out, a pair of autoimmune biotechs have eked out separate deals with Big Pharma before year-end, each with a sizable potential payout down the line. Seattle’s Adaptive Biotechnologies, ...